Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Polycystic Ovary Syndrome 1Lymphoma, Follicular 1Diabetes Mellitus, Type 2 1Dementia 1Cognitive Dysfunction 1

Interventions

XENP 1595 2mazdutide 1enzalutamide 1amlodipine, atorvastatin drug combination 1UE2343 1Tomography, X-Ray Computed 1Tomography, Emission-Computed 1Tablets 1Standard of Care 1Referral and Consultation 1Prednisone 1Positron-Emission Tomography 1Methods 1Magnetic Resonance Imaging 1Lysine Acetyltransferase 5 1Hormones 1Gonadotropin-Releasing Hormone 1Exercise 1Ethanol 1Electroencephalography 1Dignity Therapy 1Decision Support Techniques 1Atorvastatin 1Activities of Daily Living 1Accidental Falls 1Abiraterone Acetate 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Dementia × mazdutide × Clear all
NCT07083154 2026-03-05

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 3 Recruiting
420 enrolled
Lymphoid

Dementia, Diabetes Mellitus, Type 2, Lymphoma, Follicular, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡